

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

PROVECTUS BIOPHARMACEUTICALS, INC.

Form: 4

Date Filed: 2016-03-31

Corporate Issuer CIK: 315545

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Koe Jan			2. Issuer Name and Ticker or Trading Symbol PROVCTUS BIOPHARMACEUTICALS, INC. [PVCT]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> 10% Owner <input type="checkbox"/> Other (specify below)			
(Last) (First) (Middle) 1204 E. CENTRAL ROAD,, SUITE 100			3. Date of Earliest Transaction (Month/Day/Year) 03/29/2016							
(Street) ARLINGTON HEIGHTS, IL 60005			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person			
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/29/2016		O(1)		100,000	A	\$ 1.25 (1)	686,300	D	
Common Stock	03/29/2016		O(1)		100,000	A	\$ 1.25 (1)	786,300	D	
Common Stock								150,000	I	By Vekoe Partners LLC

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.	SEC 1474 (9-02)
--	--	-----------------

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Common Stock Warrants (right to buy)	\$ 1.25 (1)	03/29/2016		O(1)			100,000	06/28/2012	04/15/2016	Common Stock	100,000	(1)	0	D	
Common Stock Warrants (right to buy)	\$ 0.85	03/29/2016		O(1)			100,000	03/29/2016	06/19/2020	Common Stock	100,000	(1)	100,000	D	
Common Stock Warrants (right to buy)	\$ 1.25 (1)	03/29/2016		O(1)			100,000	04/20/2011	04/20/2016	Common Stock	100,000	(1)	0	D	
Common Stock Warrants (right to buy)	\$ 0.85	03/29/2016		O(1)			100,000	03/29/2016	06/19/2020	Common Stock	100,000	(1)	100,000	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Koe Jan 1204 E. CENTRAL ROAD, SUITE 100 ARLINGTON HEIGHTS, IL 60005	X			

Signatures

/s/ Jan E. Koe	03/31/2016
<small>**Signature of Reporting Person</small>	<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On March 29, 2016, the reporting person exercised an aggregate of 200,000 warrants pursuant to the Issuer's warrant exchange offer, at a discounted exercise price of \$0.50 per share, which exercise consisted of: (i) an exercise of 100,000 shares pursuant to a warrant issued on June 28, 2012, with an original exercise price of \$1.25 per share and (ii) an exercise of 100,000 shares (1) pursuant to a warrant issued on September 20, 2013, with an original exercise price of \$1.25 per share. Under the terms of the warrant exchange offer, holders received, in addition to the common stock acquired upon exercise of their existing warrants, an equal number of new warrants to purchase the same number of shares of the Issuer's common stock at an exercise price of \$0.85 per share that will expire June 19, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours
per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the
Investment Company Act of 1940

☐ Check this box if no
longer subject to Section
16. Form 4 or Form 5
obligations may continue.
See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person Koe Jan			2. Issuer Name and Ticker or Trading Symbol PROVCTUS BIOPHARMACEUTICALS, INC. [PVCT]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> 10% Owner <input type="checkbox"/> Other (specify below)			
(Last) (First) (Middle) 1204 E. CENTRAL ROAD,, SUITE 100			3. Date of Earliest Transaction (Month/Day/Year) 03/29/2016							
(Street) ARLINGTON HEIGHTS, IL 60005			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person			
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/29/2016		O(1)		100,000	A	\$ 1.25 (1)	686,300	D	
Common Stock	03/29/2016		O(1)		100,000	A	\$ 1.25 (1)	786,300	D	
Common Stock								150,000	I	By Vekoe Partners LLC

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.	SEC 1474 (9-02)
--	--	-----------------

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Common Stock Warrants (right to buy)	\$ 1.25 (1)	03/29/2016		O(1)			100,000	06/28/2012	04/15/2016	Common Stock	100,000	(1)	0	D	
Common Stock Warrants (right to buy)	\$ 0.85	03/29/2016		O(1)			100,000	03/29/2016	06/19/2020	Common Stock	100,000	(1)	100,000	D	
Common Stock Warrants (right to buy)	\$ 1.25 (1)	03/29/2016		O(1)			100,000	04/20/2011	04/20/2016	Common Stock	100,000	(1)	0	D	
Common Stock Warrants (right to buy)	\$ 0.85	03/29/2016		O(1)			100,000	03/29/2016	06/19/2020	Common Stock	100,000	(1)	100,000	D	

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Koe Jan 1204 E. CENTRAL ROAD, SUITE 100 ARLINGTON HEIGHTS, IL 60005	X

Signatures

/s/ Jan E. Koe	03/31/2016
<small>**Signature of Reporting Person</small>	<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On March 29, 2016, the reporting person exercised an aggregate of 200,000 warrants pursuant to the Issuer's warrant exchange offer, at a discounted exercise price of \$0.50 per share, which exercise consisted of: (i) an exercise of 100,000 shares pursuant to a warrant issued on June 28, 2012, with an original exercise price of \$1.25 per share and (ii) an exercise of 100,000 shares (1) pursuant to a warrant issued on September 20, 2013, with an original exercise price of \$1.25 per share. Under the terms of the warrant exchange offer, holders received, in addition to the common stock acquired upon exercise of their existing warrants, an equal number of new warrants to purchase the same number of shares of the Issuer's common stock at an exercise price of \$0.85 per share that will expire June 19, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.